Standout Papers

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhib... 2019 2026 2021 2023 250
  1. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors (2019)
    Guy Young, Ri Liesner et al. Blood

Immediate Impact

5 by Nobel laureates 61 from Science/Nature 96 standout
Sub-graph 1 of 22

Citing Papers

Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis
2022 Standout
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
2018 Standout

Works of Tiffany Chang being referenced

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors
2017
Liothyronine for Depression: A Review and Guidance for Safety Monitoring.
1995

Author Peers

Author Last Decade Papers Cites
Tiffany Chang 995 349 461 58 1.8k
Mark Layton 836 549 363 69 1.8k
Casey L. O’Connell 780 495 705 84 2.1k
William Krivit 535 238 315 58 1.7k
Cédric Ghevaert 1100 517 603 50 1.8k
Ashley P. Ng 505 239 521 64 1.9k
Fredrik Celsing 557 500 526 44 1.8k
Juana Ciudad 504 273 405 65 2.2k
Eul‐Ju Seo 473 216 775 109 1.8k
Jacqueline Yaouanq 577 391 184 38 1.6k
Kazumi Suzukawa 594 199 696 74 1.6k

All Works

Loading papers...

Rankless by CCL
2026